BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:lunsekimig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of lunsekimig\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06676319-1424@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20270621
DTEND;VALUE=DATE:20270622
SUMMARY:lunsekimig: Phase 2 readout est. (NCT06676319)
DESCRIPTION:lunsekimig\, phase 2\, Asthma.\nStudy: Study of Lunsekimig (SAR
 443765) Compared With Placebo in Adults With High-risk Asthma\nEstimated p
 rimary completion: 21 June 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/lunsekimig#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06676319
URL:https://assetmemo.bio/drug/lunsekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06914908-1424@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20290222
DTEND;VALUE=DATE:20290223
SUMMARY:lunsekimig: Phase 2 readout est. (NCT06914908)
DESCRIPTION:lunsekimig\, phase 2.\nStudy: Long-term Safety and Efficacy Eva
 luation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis Wi
 th Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinic
 al Study\nEstimated primary completion: 22 February 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/lunsekimig#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06914908
URL:https://assetmemo.bio/drug/lunsekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07190222-1424@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20291127
DTEND;VALUE=DATE:20291128
SUMMARY:lunsekimig: Phase 3 readout est. (NCT07190222)
DESCRIPTION:lunsekimig\, phase 3\, Chronic Obstructive Pulmonary Disease.\n
 Study: Efficacy\, Safety\, and Tolerability Study of Lunsekimig Compared W
 ith Placebo in Adult Participants With Inadequately Controlled Chronic Obs
 tructive Pulmonary Disease (COPD)\, Characterized by an Eosinophilic Pheno
 type\nEstimated primary completion: 27 November 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/lunsekimig#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07190222
URL:https://assetmemo.bio/drug/lunsekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07190209-1424@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20291127
DTEND;VALUE=DATE:20291128
SUMMARY:lunsekimig: Phase 3 readout est. (NCT07190209)
DESCRIPTION:lunsekimig\, phase 3\, Chronic Obstructive Pulmonary Disease.\n
 Study: Efficacy\, Safety\, and Tolerability Study of Lunsekimig Compared W
 ith Placebo in Adult Participants With Inadequately Controlled Chronic Obs
 tructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenoty
 pe\nEstimated primary completion: 27 November 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/lunsekimig#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07190209
URL:https://assetmemo.bio/drug/lunsekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06609239-1424@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20310120
DTEND;VALUE=DATE:20310121
SUMMARY:lunsekimig: Phase 2 readout est. (NCT06609239)
DESCRIPTION:lunsekimig\, phase 2\, Asthma.\nStudy: Long-term Safety and Eff
 icacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asth
 ma\nEstimated primary completion: 20 January 2031. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/lunsekimig#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06609239
URL:https://assetmemo.bio/drug/lunsekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07793409-1424@assetmemo.bio
DTSTAMP:20261121T005701Z
DTSTART;VALUE=DATE:20310723
DTEND;VALUE=DATE:20310724
SUMMARY:lunsekimig: Phase 3 readout est. (NCT07793409)
DESCRIPTION:lunsekimig\, phase 3\, Chronic Obstructive Pulmonary Disease.\n
 Study: A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig
  in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)\n
 Estimated primary completion: 23 July 2031. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/lunsekimig#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07793409
URL:https://assetmemo.bio/drug/lunsekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
